ArticleFrontiers in oncology2026
Primary healthcare-friendly prostate cancer prediction model using routine clinical parameters: a multicenter study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to develop and validate a nomogram model integrating routinely available parameters, making it applicable to primary healthcare settings for optimizing prostate cancer (PCa) risk stratification in patients with elevated prostate-specific antigen (PSA) levels, aiming to reduce unnecessary biopsies. Methods: This study included a retrospective cohort of 2, 844 patients who underwent prostate biopsy (885 malignant and 1, 959 benign cases), who were randomly allocated to a training set and an internal validation set in a 7:3 ratio. Independent predictive factors were selected through univariate analyses and multivariate logistic regression analyses, and a nomogram was constructed. The model's performance was evaluated using Receiver Operating Characteristic (ROC) curve analysis, precision-recall (PR) curves, calibration curve, and decision curve analysis (DCA). Further validation was conducted using an external independent dataset ( Results: The nomogram model incorporated prostate volume, total PSA (tPSA), free-to-total PSA ratio (f/t PSA), and age, demonstrating discriminative performance with AUC values of 0.816 (95% CI: 0.796-0.836; training set), 0.833 (95% CI: 0.802-0.862; internal validation set), and 0.776 (95% CI: 0.720-0.832; external validation set). Its clinically acceptable performance outperformed that of individual parameters in the training set (all p-values <0.001 by Delong's test). The ROC curve and PR curve both demonstrated the robust predictive performance of the prediction model across all three study cohorts. The calibration curve showed strong agreement between the predicted probability and actual risk. DCA confirmed clinical net benefit across a wide range of risk thresholds. Conclusion: This nomogram provides a non-invasive, cost-effective, individualized PCa risk assessment tool for Chinese patients with elevated PSA levels. Its generalizability was confirmed through external validation, demonstrating effectiveness in optimizing biopsy decisions and suitability for primary healthcare settings, thereby reducing healthcare burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.